HC Wainwright & Co. Reiterates Buy on First Wave BioPharma, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on First Wave BioPharma (NASDAQ:FWBI) and maintained a $10 price target.
June 29, 2023 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on First Wave BioPharma and maintained a $10 price target, potentially indicating positive sentiment towards the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of a 'Buy' rating and maintenance of a $10 price target by HC Wainwright & Co. suggests they believe FWBI's stock is undervalued, which could lead to increased buying pressure and a potential increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100